Abstract
The Multinational Association for Supportive Care in Cancer (MASCC) score for febrile neutropenia in cancer patients is a critical tool for identifying patients at low risk of complications, potentially suitable for oral or outpatient therapy (Table 1) [1]. The MASCC score is based on easily obtainable clinical information, has been validated multiple times [2–12] and has been used as a basis for relevant guidelines including the Australian guideline [13–16].
Original language | English |
---|---|
Pages (from-to) | 915-916 |
Number of pages | 2 |
Journal | Supportive Care in Cancer |
Volume | 21 |
Issue number | 4 |
DOIs | |
Publication status | Published - 18 Dec 2012 |
Externally published | Yes |